Immune-Checkpoint Blockade Aptamers as a Feasible Clinical Alternative to Monoclonal Antibodies

Cancer Cell & Microenvironment
doi 10.14800/ccm.1247
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

Smart Science and Technology, LLC

Related search

Masterful Antibodies: Checkpoint Blockade

Cancer immunology research
Cancer ResearchImmunology
2017English

Immune Checkpoint Blockade in Lymphoid Malignancies

FEBS Journal
BiochemistryCell BiologyMolecular Biology
2016English

Systemic Immunological Biomarkers of Clinical Responses in Immune Checkpoint Blockade Therapies

Lung Cancer Management
2018English

Immune Checkpoint Blockade for Hematologic Malignancies: A Review

Stem Cell Investigation
2017English

The FG Loop of PD-1 Serves as a ‘Hot-Spot’ for Therapeutic Monoclonal Antibodies in Tumor Immune Checkpoint Therapy

iScience
Multidisciplinary
2019English

Immune Checkpoint Blockade: Subjugation of the Masses

2017English

Inhibition of QPCTL Induces Myeloid Immune Checkpoint Blockade

Cancer Discovery
Oncology
2019English

Nodular Regenerative Hyperplasia Associated With Immune Checkpoint Blockade

Hepatology
MedicineHepatology
2018English

Monoclonal Antibodies: A Tool in Clinical Research

Indian Journal of Clinical Medicine
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy